(Asian News Hub) – A week after the WHO granted Emergency Use Listing (EUL) to Covaxin, The Lancet has published a study which found that the phase 3 data of India’s first indigenously developed vaccine demonstrates 77.8% efficacy against symptomatic Covid-19 and 70.8% protection against all variants of SARS-CoV-2.
Covaxin, which uses traditional, inactivated virus technology, “induces a robust antibody response” two weeks after two doses are given, The Lancet said in a statement.
Also Read: A Producer once told me ‘You’re so hot i can heat chapatis on your Waist’: Mallika Sherawat
No severe vaccine-related deaths or adverse events were recorded during a randomized trial involving 24,419 participants aged 18 to 97 years between November 2020 and May 2021 in India, the medical journal said.
Also Read: Hizb district commander among three militants killed in Kulgam, Srinagar encounters
Further research will be needed to discover the vaccine’s long-term safety and effectiveness, as well as protection against severe disease, hospitalization and death, along with its ability to fend off the Delta and other variants of concern, according to The Lancet.
